ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Potential Cost-Savings Associated with ANG-3777 for the Treatment of Delayed Graft Function in Kidney Transplantation

M. Cooper1, T. Mayne2, T. Kauf3, M. Gargano3, K. Freemyer3

1Medstar Georgetown Transplant Institute, Washington, DC, 2Angion Biomedica Corp, San Francisco, CA, 3Genesis Research, Hoboken, NJ

Meeting: 2020 American Transplant Congress

Abstract number: C-224

Keywords: Economics, Graft failure, Graft function, Kidney transplantation

Session Information

Session Name: Poster Session C: Non-Organ Specific: Economics & Ethics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: We created a medical cost offset model based upon the results of a Phase 2, double-blind, randomized controlled trial of ANG-3777, a hepatocyte growth factor mimetic under development for the treatment of delayed graft function (DGF).

*Methods: A cost offset model from the perspective of a US integrated disease network with a 1-year time horizon was constructed and divided into 3 follow-up periods: Month 1 (including transplant hospitalization); months 2-6; months 7-12. Model inputs and assumptions are shown in the table. Transplant hospital days, graft failure rates, and eGFRs were collected from the Phase 2 trial for ANG-3777 and placebo patients. Month 2 to 12 hospitalizations were based on a Keong (2016) analysis of post-transplant hospitalizations stratified by eGFR, which were applied to the Phase 2 data. Costs were generated via a Premier Hospital Database cost analysis and the 2018 USRDS annual data report. We inflated graft failure in the ANG-3777 arm from 0 (observed in the trial) to 5.53% to reflect epidemiologic norms for non-DGF transplant patients.

*Results: Initial hospital, rehospitalization, and graft failure costs were higher in the placebo arm of the model. Non-graft failure 7-12 month hospitalization costs were slightly higher in the ANG-3777 arm, due to the fact that fewer patients experienced graft failure. The total cost offset associated with ANG-3777 in the first year after transplantation was $39,162.

*Conclusions: The Phase 2 study demonstrated that patients treated with ANG-3777 have shorter transplant hospitalization stays, higher eGFR at 28 days and 6 months, and lower incidence of graft failure. Applying standard costs for kidney transplant patients based on direct and eGFR-derived hospitalization rates produced a potential cost saving of $39,162 supporting further and expanded investigation of ANG-3777.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cooper M, Mayne T, Kauf T, Gargano M, Freemyer K. Potential Cost-Savings Associated with ANG-3777 for the Treatment of Delayed Graft Function in Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/potential-cost-savings-associated-with-ang-3777-for-the-treatment-of-delayed-graft-function-in-kidney-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences